WJPMR, 2026, 12(2), 40-42

Review Article

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Impact Factor: 6.842

ISSN (O): 2455-3301

ISSN (P): 3051-2557

Coden USA: WJPMBB

THE ALGORITHMIC APOTHECARY: ACCELERATING DRUG DISCOVERY FROM OMICS TO OUTCOMES

Najiya J. Mulla*[1], Prajakta G. Sable[1], Alfiya C. Patel[1], Sonali S. Deshmukh[1], Piyush S. More[1], Pooja S. Bhandare[2]

B.Pharm Final Year Student, KCTS Krishna College of Pharmacy, Karad.

***Corresponding Author: Najiya J. Mulla**

B.Pharm Final Year Student, KCTS Krishna College of Pharmacy, Karad.

DOI: https://doi.org/10.5281/zenodo.18428343

How to cite this Article: Najiya J. Mulla*1, Prajakta G. Sable1, Alfiya C. Patel1, Sonali S. Deshmukh1, Piyush S. More1, Pooja S. Bhandare2 (2026). The Algorithmic Apothecary: Accelerating Drug Discovery From Omics To Outcomes. World Journal of Pharmaceutical and Medical Research, 12(2), 40–42.

Article Received on 02/01/2025 **Article Revised on 23/01/2026** **Article Published on 01/02/2026**

ABSTRACT

Artificial Intelligence (AI), encompassing Machine Learning (ML) and Deep Learning (DL), is revolutionizing traditional drug discovery, a process traditionally characterized by long timelines (10 to 17 years) and high costs (up to 2.8 billion). AI enhances efficiency, accuracy, and success rates across the pharmaceutical pipeline, accelerating target identification, *de novo* drug design, virtual screening (VS), and clinical trial optimization. Key methodologies include Neural Networks (NNs), Graph Neural Networks (GNNs), and Natural Language Processing (NLP). Despite significant promise, widespread adoption is hindered by challenges relating to data quality, model interpretability ("black box" issues), and evolving ethical/regulatory frameworks. AI integration aims to usher in an era of personalized, cost-effective, and safer therapeutics.

KEYWORDS: Artificial Intelligence, Deep Learning, Drug Discovery, Target Identification, Virtual Screening, Personalized Medicine.

INTRODUCTION

The complex and expensive nature of conventional drug discovery demands innovative solutions to improve efficiency and success rates.[1] Traditional development often spans over a decade and frequently results in failure due to poor efficacy or safety concerns. AI provides unprecedented capabilities to handle vast, unwieldy datasets, analyze complex biological systems, and support critical decision-making throughout the drug development lifecycle.[2] This technology helps identify optimal targets, accelerates molecular synthesis, and improves predictive accuracy, fundamentally reshaping research and development (R&D) paradigms. AI tools are applied across key stages, including target identification, hit/lead discovery and optimization, preclinical testing, and clinical development.[3]

Fig. no. 1: AI-Driven Drug Discovery.

METHODS/METHODOLOGIES

AI techniques are primarily categorized into Machine Learning (ML) and its subset, Deep Learning (DL).[4] ML techniques include supervised learning (used for drug efficacy and toxicity prediction based on labeled data) and unsupervised learning (used for identifying novel drug targets by clustering genes). Reinforcement Learning (RL) is used for optimizing multi-step processes like *de novo* molecular design and lead optimization by maximizing rewards.[5] DL employs deep neural networks (DNNs), leveraging multiple layers to interpret complex, high- dimensional data, often eliminating the need for manual feature engineering common in conventional ML.[6] Key architectures include Convolutional Neural Networks (CNNs) for analyzing 2D/3D molecular structures and image data, and Graph Neural Networks (GNNs) for processing graph-structured data like chemical bonds and atoms, enabling auto-learning of features.[7] Natural Language Processing (NLP) extracts insights from unstructured textual data such as scientific literature and Electronic Health Records (EHRs) for target discovery and drug repurposing.[8]



Fig. no. 2: AI Methodologies In Drug Discovery.

Tools Used: A diverse suite of specialized AI tools drives modern drug discovery. AlphaFold, an AI system by DeepMind, is renowned for accurately predicting the three-dimensional (3D) structure of proteins, revolutionizing structure-based drug design.[9] Generative Adversarial Networks (GANs) are utilized for *de novo* generation of novel molecular structures with specific properties. Predictive models like Deep Tox and ADMET lab 2.0/3.0 are crucial for predicting toxicity and ADMET properties (Absorption, Distribution, Metabolism, Excretion, and Toxicity) early in development. Other major platforms include Benevolent AI (knowledge graphs/repurposing), Atom wise (virtual screening), In silico Medicine (Panda Omics/GENTRL for novel targets/molecules), and Schrödinger's Maestro platform (molecular modeling/QSAR).[9,10]



Fig. no. 3: AI Tools Used In Drug Discovery.

Advantages

1. AI integration significantly reduces drug development timelines by accelerating discovery and early testing processes.
2. It lowers overall research and development costs by optimizing experiments and minimizing trial failures.[11]
3. AI increases clinical trial success rates by accurately predicting drug efficacy, safety, and toxicity at early stages.
4. It enables personalized medicine by analyzing genetic and multi-omics data to design patient-specific therapies.[12]

Disadvantages/Challenges

1. A major limitation is the heavy reliance on large, high-quality, unbiased datasets, as poor or fragmented data reduces model reliability and applicability.
2. The lack of interpretability in deep learning "black box" models creates transparency issues, reducing regulatory acceptance and clinician confidence.[13]
3. Ethical challenges such as algorithmic bias and risks to patient data privacy raise serious concerns about fairness and compliance with legal standards.
4. High computational requirements and the need for specialized technical expertise limit cost-effective and widespread implementation of AI systems.[14]

Future Prospective

Future developments focus heavily on Explainable AI (XAI) frameworks to enhance transparency and clinical trust.[15] Continued efforts will integrate multimodal data (genomics, proteomics, EHRs, imaging) to build more comprehensive and complex models that reflect real biological contexts.[16] Advances in personalized federated learning offer solutions for secure data sharing and personalized drug development.[17] Regulatory bodies are actively developing frameworks to accommodate AI-driven methodologies, focusing on transparency and validation metrics to ensure patient safety and responsible innovation.[18]

CONCLUSION

AI represents an irreversible, transformative shift in pharmaceutical R&D, offering enhanced efficiency and reduced costs across the entire pipeline. While core challenges like data quality and model transparency persist, the combination of human scientific expertise and powerful AI tools often yields superior outcomes

compared to either acting alone. By prioritizing collaborative efforts, data standardization, and ethical governance, the pharmaceutical industry is poised to leverage AI's full potential to deliver faster, safer, and more personalized medicines globally.

REFERENCES

1. Boomisha S. D.JCH. AI in Drug Discovery. 2025 Feb 21 [cited 2025 Dec 15]; Available from: https://zenodo.org/doi/10.5281/zenodo.14907864
2. Duan FL, Duan CB, Xu HL, Zhao XY, Sukhbaatar O, Gao J, et al. AI-driven drug discovery from natural products. Adv Agrochem, Sept. 2024; 3(3): 185–7.
3. Ferreira FJN, Carneiro AS. AI-Driven Drug Discovery: A Comprehensive Review. ACS Omega, June. 17, 2025; 10(23): 23889–903.
4. Nilesh Savale*. Artificial Inteligence Used in Drug Discovery. 2025 Mar 3 [cited 2025 Dec 15]; Available from: https://zenodo.org/doi/10.5281/zenodo.14961715
5. Serrano DR, Luciano FC, Anaya BJ, Ongoren B, Kara A, Molina G, et al. Artificial Intelligence (AI) Applications in Drug Discovery and Drug Delivery: Revolutionizing Personalized Medicine. Pharmaceutics, Oct. 14, 2024; 16(10): 1328.
6. Bhat AR, Ahmed S. Artificial intelligence (AI) in drug design and discovery: A comprehensive review. Silico Res Biomed, 2025; 1: 100049.
7. Chen W, Liu X, Zhang S, Chen S. Artificial intelligence for drug discovery: Resources, methods, and applications. Mol Ther - Nucleic Acids, Mar. 2023; 31: 691–702.
8. Niazi SK, Mariam Z. Artificial intelligence in drug development: reshaping the therapeutic landscape. Ther Adv Drug Saf., Jan. 2025; 16: 20420986251321704.
9. Krosuri P, Pravallika G, Paravathi G, Sumanasri J, Akhila C, SriNikitha S. ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY, 1001.
10. Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discov Pharm Sci., June 2, 2025; 1(1): 7.
11. Herráiz-Gil S, Nygren-Jiménez E, Acosta-Alonso DN, León C, Guerrero-Aspizua S. Artificial Intelligence-Based Methods for Drug Repurposing and Development in Cancer. Appl Sci., Mar. 5, 2025; 15(5): 2798.
12. Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, Ganokratanaa T, Suwanpitak K, et al. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. Eur J Pharm Sci., Dec. 2024; 203: 106938.
13. Visan AI, Negut I. Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery. Life., Feb. 7, 2024; 14(2): 233.
14. Dhudum R, Ganeshpurkar A, Pawar A. Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications. Drugs Drug Candidates, Feb. 13, 2024; 3(1): 148–71.
15. Yadav S, Singh A, Singhal R, Yadav JP. Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. Intell Pharm., June 2024; 2(3): 367–80.
16. Fu C, Chen Q. The future of pharmaceuticals: Artificial intelligence in drug discovery and development. J Pharm Anal, Aug. 2025; 15(8): 101248.
17. Faculty of Engineering Kampala International University Uganda, Kwemoi KC. The Role of Artificial Intelligence in Accelerating Drug Discovery Innovations. Res Invent J Sci Exp Sci., Mar. 3, 2025; 5(1): 9–13.
18. Wu Y, Ma L, Li X, Yang J, Rao X, Hu Y, et al. The role of artificial intelligence in drug screening, drug design, and clinical trials. Front Pharmacol, Nov. 29, 2024; 15: 1459954.